XTX Topco Ltd Has $997,000 Stake in Dynavax Technologies Corporation (NASDAQ:DVAX)

Key Points

• XTX Topco Ltd increased its stake in Dynavax Technologies Corporation by 57.0% to approximately $997,000 in the first quarter.
• Deerfield Management Company L.P. Series C significantly raised its position in Dynavax by 23,990.1%, now owning shares valued at $66,325,000.
• Analysts have recently adjusted their target prices for Dynavax, with JMP Securities reducing it from $33.00 to $31.00 while maintaining a "market outperform" rating.

XTX Topco Ltd grew its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 57.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,854 shares of the biopharmaceutical company's stock after acquiring an additional 27,893 shares during the quarter. XTX Topco Ltd owned 0.06% of Dynavax Technologies worth $997,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Bryce Point Capital LLC acquired a new position in shares of Dynavax Technologies in the first quarter valued at approximately $357,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Dynavax Technologies by 4.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,920 shares of the biopharmaceutical company's stock worth $401,000 after acquiring an additional 1,453 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in Dynavax Technologies in the 1st quarter valued at $292,000. Choreo LLC increased its position in shares of Dynavax Technologies by 3.2% in the first quarter. Choreo LLC now owns 34,828 shares of the biopharmaceutical company's stock valued at $452,000 after acquiring an additional 1,065 shares during the last quarter. Finally, Moloney Securities Asset Management LLC acquired a new position in shares of Dynavax Technologies during the 1st quarter worth approximately $131,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Upgrades and Downgrades

DVAX has been the topic of several recent analyst reports. Wall Street Zen lowered shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. Finally, JMP Securities cut their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Stock Performance

Shares of Dynavax Technologies stock traded up $0.05 during trading on Wednesday, reaching $11.20. The company's stock had a trading volume of 243,349 shares, compared to its average volume of 2,093,333. The company has a quick ratio of 10.84, a current ratio of 11.93 and a debt-to-equity ratio of 0.49. The business's 50-day moving average price is $10.43 and its 200-day moving average price is $11.59. Dynavax Technologies Corporation has a 52 week low of $9.22 and a 52 week high of $14.63. The firm has a market cap of $1.34 billion, a PE ratio of -21.53 and a beta of 1.09.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.14). Dynavax Technologies had a negative net margin of 20.39% and a positive return on equity of 3.59%. The business had revenue of $68.16 million during the quarter, compared to the consensus estimate of $70.01 million. Equities analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.